Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment. pdfRead

Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer. pdfRead

Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study. pdfread

Sensorion announces the full conversion of Sofinnova Partners convertible bonds into ordinary shares. pdfRead

Sensorion announces the full conversion of Invus convertible bonds into ordinary shares. pdfRead

Pipeline

20200910 pipeline

Enregistrer

Patient center

Corporate presentation